Extended nirmatrelvir–ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial
- 15 July 2025
- journal article
- research article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 25 (11) , 1243-1253
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Research and Development
- National Institute of Allergy and Infectious Diseases (UM1AI068614, R01AI34878)
This publication has 23 references indexed in Scilit:
- Persistent COVID-19 in immunocompromised patients—Israeli society of infectious diseases consensus statement on diagnosis and managementClinical Microbiology and Infection, 2024
- Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: a systematic review and meta-analysisThe Lancet Microbe, 2024
- Clinical phenotype and outcome of persistent SARS-CoV-2 replication in immunocompromised hosts: a retrospective observational study in the Omicron eraInfection, 2023
- The relationship between vaccine acceptance and COVID-19 mortality in Europe: A Cross-Country analysis of public opinion and Epidemiological dataVaccine: X, 2023
- Nirmatrelvir/ritonavir for the treatment of immunocompromised adult patients with early‐stage symptomatic COVID‐19: A real‐life experienceJournal of Medical Virology, 2023
- Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care systemThe Lancet Infectious Diseases, 2023
- Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort studyThe Lancet Infectious Diseases, 2023
- De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case reportNature Communications, 2022
- Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid reviewThe Lancet Global Health, 2022
- SARS-CoV-2 evolution during treatment of chronic infectionNature, 2021